We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+1.57%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.92B
AUM Growth
+$129M
Cap. Flow
+$37.9M
Cap. Flow %
1.97%
Top 10 Hldgs %
49.82%
Holding
94
New
22
Increased
32
Reduced
16
Closed
13

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$65.4M
2
EW icon
Edwards Lifesciences
EW
+$64.1M
3
RAPP
Rapport Therapeutics
RAPP
+$45.2M
4
ALGN icon
Align Technology
ALGN
+$34.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$23M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$85.9M
2
INCY icon
Incyte
INCY
+$75.6M
3
ARGX icon
argenx
ARGX
+$58.8M
4
INBX
Inhibrx, Inc. Common Stock
INBX
+$45.5M
5
PODD icon
Insulet
PODD
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 82.42%
2 Miscellaneous 17.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INBX icon
51
Inhibrx
INBX
$1.66B
$6.57M 0.34%
+463,315
New +$7.24M
ACHV icon
52
Achieve Life Sciences
ACHV
$776M
$6.53M 0.34%
1,388,372
-129,858
-9% -$626K
WAT icon
53
Waters Corp
WAT
$39.8B
$6.33M 0.33%
+21,804
New +$6.96M
JBIO
54
Jade Biosciences
JBIO
$1.21B
$6.24M 0.32%
107,391
– –
FDMT icon
55
4D Molecular Therapeutics
FDMT
$783M
$5.69M 0.3%
271,155
+72,969
+37% +$1.83M
MRNS
56
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.86M 0.25%
4,151,576
+2,750,523
+196% +$6.88M
NXTC icon
57
NextCure
NXTC
$36.9M
$4.25M 0.22%
222,655
– –
ERAS icon
58
Erasca
ERAS
$5.49B
$4.01M 0.21%
+1,699,528
New +$3.67M
PAHC icon
59
Phibro Animal Health
PAHC
$1.49B
$3.97M 0.21%
+237,009
New +$3.81M
BAX icon
60
Baxter International
BAX
$12.6B
$3.94M 0.2%
117,769
+97,769
+489% +$3.6M
AVTR icon
61
Avantor
AVTR
$10.1B
$2.99M 0.16%
141,045
-91,401
-39% -$2.2M
TFX icon
62
Teleflex
TFX
$5.75B
$2.87M 0.15%
13,649
+1,507
+12% +$316K
MASI
63
DELISTED
Masimo
MASI
$2.54M 0.13%
20,161
+161
+0.8% +$21.2K
BOLT icon
64
Bolt Biotherapeutics
BOLT
$7.09M
$2.07M 0.11%
137,722
– –
INSP icon
65
Inspire Medical Systems
INSP
$1.92B
$1.34M 0.07%
10,000
+1,901
+23% +$360K
IRON icon
66
Disc Medicine
IRON
$2.94B
$1.32M 0.07%
29,256
+23,083
+374% +$784K
CATX icon
67
Perspective Therapeutics
CATX
$341M
$1.32M 0.07%
132,089
+89,078
+207% +$1.29M
ZBH icon
68
Zimmer Biomet
ZBH
$18B
$1.15M 0.06%
+10,630
New +$1.25M
LIVN icon
69
LivaNova
LIVN
$4.35B
$1.13M 0.06%
20,602
+146
+0.7% +$8.32K
IMTXW
70
DELISTED
Immatics N.V. Warrants
IMTXW
$933K 0.05%
348,731
+32,382
+10% +$91K
RNAM
71
DELISTED
Avidity Biosciences
RNAM
$875K 0.05%
+21,425
New +$615K
IMA
72
ImageneBio Inc
IMA
$56.9M
$631K 0.03%
31,885
– –
SVRA icon
73
PUT
Savara
SVRA
$1.11B
$605K 0.03%
+150,000
New +$667K
AMLX icon
74
PUT
Amylyx Pharmaceuticals
AMLX
$3.61B
$570K 0.03%
300,000
– –
AMLX icon
75
Amylyx Pharmaceuticals
AMLX
$3.61B
$569K 0.03%
299,691
-7,038
-2% -$13.6K
1 2
3
4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q2 2024 Portfolio in Review

As of Q2 2024, Sofinnova Investments held 94 positions worth $1.92B, up 7.2% from $1.8B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sofinnova Investments's Q2 2024 filing shows 22 new, 32 increased, 16 reduced and 13 closed positions. Its largest new stake was Stryker: 193,084 shares worth $65.7M. The largest sale was Merck, an estimated $85.9M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

  • Sofinnova Investments's largest Q2 2024 buy was Stryker: 193,084 shares worth $65.7M.
  • Sofinnova Investments added most to Align Technology in Q2 2024, an estimated $34.3M increase.
  • Sofinnova Investments's biggest Q2 2024 reduction was Insulet, cutting an estimated $28.7M.
  • Sofinnova Investments fully exited Merck in Q2 2024, selling an estimated $85.9M.
  • Sofinnova Investments's ten largest holdings make up 50% of its $1.92B portfolio in Q2 2024.
  • Sofinnova Investments opened 22 new positions and closed 13 in Q2 2024.
  • Sofinnova Investments's portfolio value rose 7.2% quarter-over-quarter to $1.92B.

Based on Sofinnova Investments's 13F filing for Q2 2024, filed 9 Aug 2024.